Pharsight

Nuplazid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7923564 ACADIA PHARMS INC Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Sep, 2025

(1 year, 11 months from now)

US7732615 ACADIA PHARMS INC N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
Jun, 2028

(4 years from now)

US7601740 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Apr, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9765053 ACADIA PHARMS INC Methods of treatment using selective 5-HT2A inverse agonists
Jul, 2022

(1 year, 2 months ago)

US10028944 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US9566271 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US8618130 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US8921393 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US7659285 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Aug, 2026

(2 years from now)

US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(13 years from now)

US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(13 years from now)

US11452721 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

US10849891 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

US10449185 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

US10646480 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

Nuplazid is owned by Acadia Pharms Inc.

Nuplazid contains Pimavanserin Tartrate.

Nuplazid has a total of 15 drug patents out of which 1 drug patent has expired.

Expired drug patents of Nuplazid are:

  • US9765053

Nuplazid was authorised for market use on 29 April, 2016.

Nuplazid is available in tablet;oral dosage forms.

Nuplazid can be used as treatment of parkinson's disease psychosis, treatment of psychosis or a symptom thereof, treatment of a neurodegenerative disease or a symptom thereof, treatment of hallucinations and delusions associated with parkinson's disease psychosis.

The generics of Nuplazid are possible to be released after 27 August, 2038.

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of psychosis or a symptom thereof; Treatment of a neurodegenerative disease or a symptom thereof; Tre...

Dosage: TABLET;ORAL

How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage

NUPLAZID family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic